These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Fluoride substitution of vitamin D analogs at C-26 and C-27: enhancement of activity of 25-hydroxyvitamin D but not of 1,25-dihydroxyvitamin D on bone and intestine in vitro.
    Author: Stern PH, Mavreas T, Tanaka Y, DeLuca HF, Ikekawa N, Kobayashi Y.
    Journal: J Pharmacol Exp Ther; 1984 Apr; 229(1):9-13. PubMed ID: 6323693.
    Abstract:
    A series of analogs of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] with multiple fluorine substitutions in positions 26 and 27 have been tested for their activities 1) in competing with 1,25-(OH)2D3 for binding to partially purified chick intestinal cytosol, 2) in stimulating resorption of fetal rat limb bones in vitro and 3) in competing with 25-hydroxyvitamin D3 for binding sites in rat plasma. The relative potencies of 26,26,26,27,27,27-hexafluoro-25-hydroxyvitamin D3, 26,26,26-trifluoro-25-hydroxyvitamin D3, 27-nor-26,26,26-trifluoro-25-hydroxyvitamin D3 and 25-hydroxyvitamin D3 in competing for intestinal cytosolic binding were 17:11:1:1. The relative potencies of the same series of compounds on stimulating resorption of fetal rat bones was 25:21:9:1. The relative ability of these four compounds to compete for plasma binding sites was 0.3:0.3:0.4:1.0. The results indicate that multiple fluorine substitution in the vicinity of the 25-hydroxyl group can markedly enhance the direct effects of 25-hydroxyvitamin D3 on its target tissues. This is postulated to result from the electronegativity of the fluorines which increases the acidity of the 25-hydroxyl group and enhances its affinity for the receptor. In contrast to the effects seen with the 25-hydroxyvitamin D3 analogs, multiple fluorine substitution in positions 26 and 27 did not enhance the activity of 1,25-(OH)2D3 on either cytosolic binding or bone resorption. Presumably, this is because biological activity, expressed in terms of affinity for the receptor, is already optimal in the 1,25-(OH)2D3 structure. The relative activities of the 26,27-hexafluoro derivative and 1,25-(OH)2D3 in competition for the plasma binding sites was 0.4:1.0.(ABSTRACT TRUNCATED AT 250 WORDS)
    [Abstract] [Full Text] [Related] [New Search]